| Objective:To evaluate the clinical effect of Xiaoyao Jieyu prescription on poststroke depression and persistent postpara-perceptual dizziness,as well as its effect on serum tumor necrosis factor-alpha and hypersensitive c-reactive protein,and to explore the effect of Xiaoyao Jieyu prescription in treatment of emotional diseases based on the "Treating Different Diseases with Same Method Theory"Method:Clinical trial 1:Fifty-two patients diagnosed with post-stroke depression were randomly divided into the experimental group and the control group.Routine treatment was given to both groups of patients,including drugs to treat cerebrovascular disease,neurotrophic drugs and rehabilitation therapy.On this basis,oral administration of Xiaoyao Jieyu prescription and fluoxetine hydrochloride was given to the experimental group and the control group respectively,and the treatment cycle was 12weeks.The two groups of patients were assessed for their improvement before and after treatment at the weekends of 4,8 and 12 according to the neuropsychiatric scale(NIHSS)and the Hamilton depression scale(HAMD).At the same time,changes in serum TNF-a and hs-CRP of the two groups were detected before and after treatment,and adverse reactions in the two groups during treatment were observed.Clinical trial 2:Thirty-three patients diagnosed with persistent postural perceptual dizziness were randomly divided into an experimental group and a control group.Both groups of patients were given psychological counseling and verbal hints to eliminate patient tension.On this basis,oral administration of Xiaoyao Jieyu prescription and escitalopram was given to the experimental group and the control group respectively,and the treatment cycle was 12 weeks.Based on the degree rating scale of vertigo disability(DHI),Hamilton depression scale(HAMD)and Hamilton anxiety scale(HAMA),the improvement of the two groups of patients before and after treatment at the weekends of 4,8 and 12 was evaluated,and the adverse reactions of the two groups of patients during the treatment were observed.Result:Clinical trial 1:①In the improvement of NIHSS and HAMD scores of neuropsychiatric scales,there was significant difference between the two groups at 4 weeks after treatment and before treatment(P<0.05),and there were significant differences between the experimental group and the control group at 8and 12weeks after treatment(P<0.05).②In terms of clinical efficacy,there was no significant difference in the total effective rate between the two groups at 4 weeks after treatment(P>0.05),and the experimental group showed significant difference at 8 and 12 weeks after treatment compared with the control group(P<0.05),which was significantly higher than the control group.③In terms of changes in TNF-α and hs-CRP,there was a significant difference between the two groups at 4 weeks after treatment and before treatment(P<0.05),and there was a significant difference between the experimental group at 8 weeks and 12 weeks after treatment compared with the control group(P<0.05).④In terms of adverse reactions,the incidence of adverse reactions in the experimental group was significantly lower than that in the control group during the treatment,with a significant difference between the two types(P<0.05).In addition,the adverse reactions in the experimental group were mild and easy to deal with,and there was no case shedding due to drug resistance.Clinical trial 2:①In terms of neuropsychiatric scale scores,the total score of HAMA,HAMD,DHI and all factors of the two groups at 4 weeks and 8 weeks after treatment were significantly lower than that before treatment and 4 weeks after treatment(P interval 0.01).The HAMA and HAMD scores at 12 weeks after treatment were significantly lower than those at 8 weeks after treatment(P interval 0.01).The scores of mood E and DHI in the experimental group were significantly lower at 12 weeks after treatment than at 8 weeks after treatment in the control group(P<0.01).Compared with the control group,the total DHI score and function F score of the experimental group at 8 and 12 weeks after treatment were significantly lower than those of the control group at the same time(P<0.05).The HAMA and HAMD scores of the experimental group at 4 weeks,8 weeks and 12 weeks after treatment were significantly different from those of the control group at the same time(P<0.05).② In terms of clinical efficacy,after 12 weeks of treatment,the total effective rate of the experimental group was 94.12%,and that of the control group was 73.33%.The difference between the two groups was statistically significant(P<0.05).③On the side of adverse reactions,one patient in the experimental group experienced adverse reactions,mainly because she felt that Chinese medicine tasted too bitter.After patient explanation to the patient,she kept taking the medicine.In the control group,there were 6 cases of adverse reactions,including 1 case of constipation,1 case of loss of appetite,1 case of dry mouth,1 case of drowsiness,1 case of insomnia,and 1 case of dizziness worsened after 1 week of taking medicine,unable to continue taking the medicine,and eventually fell off.The above adverse reactions were normal after symptomatic treatment or withdrawal.The difference between the two groups was statistically significant(P<0.05).Conclusion:1.Xiaoyao Jieyu prescription can significantly reduce the clinical symptoms of patients,improve the neurological functional defects and improve the quality of life of patients with post-stroke depression,and has obvious intervention effects on the contents of TNF-α and hs-CRP.In addition,this study suggested that TNF-α,hs-CRP and NIHSS scores were closely related to the occurrence of PSD.2.Xiaoyao Jieyu prescription can significantly alleviate the clinical symptoms of the patients,reduce the score of functional and physiological symptoms in the vertigo disability rating scale,and reduce the degree of dizziness,anxiety and depression of the patients with persistent postural and perceptual dizziness.3.Xiaoyao Jieyu prescription can significantly reduce the level of tumor necrosis factor-radiation and hypersensitive c-reactive protein in serum,and achieve therapeutic effect by inhibiting the immune-stress-inflammation"reaction.4.Xiaoyao Jieyu prescription had fewer adverse reactions in the treatment of post-stroke depression and persistent postpartum sensory-perceptual dizziness,and even the occurrence of adverse reactions was relatively light. |
PDF Full Text Request